Imjudo (tremelimumab-actl) injection

Imjudo is indicated for the treatment of unresectable hepatocellular carcinoma (uHCC) and metastatic non-small cell lung cancer (NSCLC). Patients should be monitored for multiple immune-related conditions. Imjudo may cause fetal harm when administered to a pregnant woman. The safety and effectiveness of Imjudo in pediatric patients less than 18 years of age have not been established. <a id="